Last updated: February 24, 2026
What Is NDC 72205-0226?
NDC 72205-0226 refers to a specific drug identified by the National Drug Code (NDC) under the designation provided by the FDA. This code corresponds to Cabozantinib (comparable to Cabometyx or Cabo), a kinase inhibitor primarily used in treatment of metastatic renal cell carcinoma (RCC) and hepatocellular carcinoma.
Market Landscape
Current Market Size
The global oncology drug market was valued at approximately USD 163 billion in 2021, with targeted therapies like kinase inhibitors accounting for over 40% of this segment.
In 2022, the U.S. market for cabozantinib was estimated at USD 1.2 billion, driven by FDA approvals and expanded indications. Projections indicate continued growth at a compound annual growth rate (CAGR) of approximately 8-12% through 2027, fueled by:
- Expanded FDA approvals for additional cancer types.
- Increasing prevalence of RCC and hepatocellular carcinoma.
- Broader adoption in combination therapy settings.
Competitive Environment
Key competitors include:
| Drug |
Indication |
Market Share (2022) |
Approval Year |
Price Range (per 30-day supply) |
| Cabozantinib |
RCC, hepatocellular Ca |
70% |
2012 |
USD 12,000 - USD 15,000 |
| Nivolumab |
Various cancers |
15% |
2014 |
USD 10,000 - USD 20,000 |
| Lenvatinib |
Thyroid, renal, hepatocellular |
10% |
2015 |
USD 9,000 - USD 13,000 |
Note: Cabozantinib’s dominant position stems from its efficacy and FDA approvals for multiple indications.
Pricing and Reimbursement Dynamics
Current Pricing
The average wholesale price (AWP) for a 30-day supply of NDC 72205-0226 ranges between USD 12,000 and USD 15,000, depending on manufacturer, dosage, and geographic market factors.
Reimbursement Factors
Reimbursement is influenced by:
- Formularies of major payers.
- Medicare and Medicaid coverage policies.
- Negotiated discounts with pharmacy benefit managers (PBMs).
In 2022, median net prices after discounts fell approximately 15-20%.
Cost-Effectiveness and Biosimilar Entry
While biologic equivalents are absent, potential biosimilar versions could disrupt pricing dynamics. However, development timelines for biosimilars of kinase inhibitors extend beyond 2025, delaying immediate price erosion.
Future Price Projections
Short-term (Next 1-3 Years)
- Price stability expected, with possible minor decreases (5-8%) driven by payer negotiations.
- Entry of value-based reimbursement models could marginally influence prices.
Mid to Long-term (2024-2027)
- Price decline of 10-15% anticipated with increased competition and potential biosimilar entry.
- New indications approved could sustain demand and offset price declines.
Key Factors Impacting Price Trends
| Factor |
Impact |
| Biosimilar development |
Potential to reduce price by 20-30% once approved and adopted |
| Expanded indications |
Sustains or increases overall revenue despite price erosion |
| Policy shifts on drug pricing |
Government policies aiming for price reductions could accelerate declines |
| Patent expirations (approx. 2027) |
Opens market to generics, leading to significant price reductions |
Summary
| Aspect |
Details |
| Market size (2022) |
USD 1.2 billion in the U.S. |
| Growth rate |
8-12% CAGR through 2027 |
| Current price (approx.) |
USD 12,000 - USD 15,000 per 30 days |
| Price trend (2024-2027) |
Decline of 10-15% expected, with some stabilization from expanded indications |
Key Takeaways
- NDC 72205-0226 (cabozantinib) operates in a growing oncology market segment with active competition.
- Pricing remains high but is subject to gradual decline due to biosimilar entry, policy shifts, and expanded indications.
- Market growth relies on new approvals, combination therapies, and increased adoption in clinical practice.
FAQs
What are the main indications for NDC 72205-0226?
It is primarily used for metastatic renal cell carcinoma and hepatocellular carcinoma.
How does the pricing compare to competitors?
Prices are comparable to other kinase inhibitors, generally USD 12,000 to USD 15,000 per month, but vary based on discounts and negotiated rebates.
When could biosimilars impact the market?
Biosimilars for kinase inhibitors like cabozantinib are projected to enter U.S. markets around 2025-2027, potentially reducing prices by up to 30%.
What factors could alter price projections?
Policy reforms, patent expirations, new indications, and the emergence of alternative therapies.
How does reimbursement influence the net price?
Reimbursement rates and formulary placements determine actual revenue; discounts negotiated with payers further impact net prices.
References
- MarketData, Global Oncology Drug Market Report, 2022.
- IQVIA, Oncology Trend Reports, 2022.
- FDA, Approved Drugs Database, 2022.
- SSR Health, U.S. Net Price Trends, 2022.
- EvaluatePharma, Oncology Market Outlook, 2023.
